Skip Nav Destination
Issues
1 January 2010
-
Cover Image
Cover Image
![issue cover]()
Targeting Cdk-2 in lung cancer was found to engage a previously unrecognized mechanism: induced anaphase catastrophe. This triggers apoptosis in lung cancer cells. The immunofluorescent image of a representative lung cancer cell is shown following small interfering RNA targeting of Cdk-2. In this image, microtubules are displayed in red and DNA in blue within a multipolar lung cancer cell undergoing anaphase catastrophe. For further details, please see the article by Galimberti and colleagues on page 109 of this issue.Close Modal - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
CCR Translations
Molecular Pathways
Review
Human Cancer Biology
Aldehyde Dehydrogenase 1–Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer
Emmanuelle Charafe-Jauffret; Christophe Ginestier; Flora Iovino; Carole Tarpin; Mark Diebel; Benjamin Esterni; Gilles Houvenaeghel; Jean-Marc Extra; François Bertucci; Jocelyne Jacquemier; Luc Xerri; Gabriela Dontu; Giorgio Stassi; Yi Xiao; Sanford H. Barsky; Daniel Birnbaum; Patrice Viens; Max S. Wicha
Chromosome 8p Deletions and 8q Gains are Associated with Tumor Progression and Poor Prognosis in Prostate Cancer
Alexander T. El Gammal; Michael Brüchmann; Jozef Zustin; Hendrik Isbarn; Olaf J.C. Hellwinkel; Jens Köllermann; Guido Sauter; Ronald Simon; Waldemar Wilczak; Jörg Schwarz; Carsten Bokemeyer; Tim H. Brümmendorf; Jakob R. Izbicki; Emre Yekebas; Margit Fisch; Hartwig Huland; Markus Graefen; Thorsten Schlomm
Inhibitor of Differentiation 1 Contributes to Head and Neck Squamous Cell Carcinoma Survival via the NF-κB/Survivin and Phosphoinositide 3-Kinase/Akt Signaling Pathways
Jizhen Lin; Zhong Guan; Chuan Wang; Ling Feng; Yiqing Zheng; Emiro Caicedo; Ellalane Bearth; Jie-Ren Peng; Patrick Gaffney; Frank G. Ondrey
Mining Tissue Microarray Data to Uncover Combinations of Biomarker Expression Patterns that Improve Intermediate Staging and Grading of Clear Cell Renal Cell Cancer
Corinne Dahinden; Barbara Ingold; Peter Wild; Gunther Boysen; Van-Duc Luu; Matteo Montani; Glen Kristiansen; Tullio Sulser; Peter Bühlmann; Holger Moch; Peter Schraml
Cancer Therapy: Preclinical
Targeting of Bone-Derived Insulin-Like Growth Factor-II by a Human Neutralizing Antibody Suppresses the Growth of Prostate Cancer Cells in a Human Bone Environment
Taichi Kimura; Takeshi Kuwata; Satoshi Ashimine; Manabu Yamazaki; Chisako Yamauchi; Kanji Nagai; Akashi Ikehara; Yang Feng; Dimiter S. Dimitrov; Seiichi Saito; Atsushi Ochiai
Vorinostat Enhances the Activity of Temsirolimus in Renal Cell Carcinoma Through Suppression of Survivin Levels
Devalingam Mahalingam; Ernest C. Medina; Juan A. Esquivel, II; Claudia M. Espitia; Sabrina Smith; Kelli Oberheu; Ronan Swords; Kevin R. Kelly; Monica M. Mita; Alain C. Mita; Jennifer S. Carew; Francis J. Giles; Steffan T. Nawrocki
The Telomerase Antagonist, Imetelstat, Efficiently Targets Glioblastoma Tumor-Initiating Cells Leading to Decreased Proliferation and Tumor Growth
Calin O. Marian; Steve K. Cho; Brian M. Mcellin; Elizabeth A. Maher; Kimmo J. Hatanpaa; Christopher J. Madden; Bruce E. Mickey; Woodring E. Wright; Jerry W. Shay; Robert M. Bachoo
Immunotherapy for Human Renal Cell Carcinoma by Adoptive Transfer of Autologous Transforming Growth Factor β–Insensitive CD8+ T Cells
Longxin Wang; Weihong Wen; Jianlin Yuan; Brian Helfand; Yu Li; Changhong Shi; Feng Tian; Jia Zheng; Fuli Wang; Lin Chen; Lili Liang; Liqun Zhou; Chung Lee; Zhinan Chen; Yinglu Guo; He Wang; Qiang Zhang; Weijun Qin
c-Jun-NH2-kinase-1 Inhibition Leads to Antitumor Activity in Ovarian Cancer
Pablo Vivas-Mejia; Juliana Maria Benito; Ariel Fernandez; Hee-Dong Han; Lingegowda Mangala; Cristian Rodriguez-Aguayo; Arturo Chavez-Reyes; Yvonne G. Lin; Mark S. Carey; Alpa M. Nick; Rebecca L. Stone; Hye Sun Kim; Francois-Xavier Claret; William Bornmann; Bryan T.J. Hennessy; Angela Sanguino; Zhengong Peng; Anil K. Sood; Gabriel Lopez-Berestein
Imaging, Diagnosis, Prognosis
Cancer Therapy: Clinical
Phase 1b Study of Motesanib, an Oral Angiogenesis Inhibitor, in Combination with Carboplatin/Paclitaxel and/or Panitumumab for the Treatment of Advanced Non–Small Cell Lung Cancer
George R. Blumenschein, Jr.; Karen Reckamp; G. Joe Stephenson; Timothy O'Rourke; Gregory Gladish; Jesse McGreivy; Yu-Nien Sun; Yining Ye; Mandy Parson; Alan Sandler
K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate
B. Douglas Smith; Yvette L. Kasamon; Jeanne Kowalski; Christopher Gocke; Kathleen Murphy; Carole B. Miller; Elizabeth Garrett-Mayer; Hua-Ling Tsai; Lu Qin; Christina Chia; Barbara Biedrzycki; Thomas C. Harding; Guang Haun Tu; Richard Jones; Kristen Hege; Hyam I. Levitsky
A Phase I Trial of Bortezomib with Temozolomide in Patients with Advanced Melanoma: Toxicities, Antitumor Effects, and Modulation of Therapeutic Targets
Yingjun Su; Katayoun I. Amiri; Linda W. Horton; Yingchun Yu; Gregory D. Ayers; Elizabeth Koehler; Mark C. Kelley; Igor Puzanov; Ann Richmond; Jeffrey A. Sosman
Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors
William P. Tew; Michael Gordon; John Murren; Jakob Dupont; Sandra Pezzulli; Carol Aghajanian; Paul Sabbatini; David Mendelson; Lawrence Schwartz; Scott Gettinger; Amanda Psyrri; Jesse M. Cedarbaum; David R. Spriggs
Letters to the Editor
Correction
Highlights
Advertisement
